Clinical Trials
22 trialsNCT07137416 2026-05-27
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT04585958 2026-05-20
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT05372614 2026-05-18
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
National Cancer Institute (NCI)
Phase 1 Suspended
NCT04704661 2026-05-13
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT06364410 2026-05-13
Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT07553390 2026-04-28
Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast Cancers
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT04686305 2026-04-13
DL03
AstraZeneca
Phase 1 Recruiting
NCT07015697 2026-03-20
A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors
Daiichi Sankyo
Phase 1 Recruiting
NCT07454668 2026-03-06
Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases
Baptist Health South Florida
Phase 1 Not yet recruiting
NCT04294628 2026-02-27
Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT06244485 2026-02-04
A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors
Daiichi Sankyo
Phase 1 Recruiting
NCT05633979 2026-01-20
Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT04556773 2025-12-17
DB-08
AstraZeneca
Phase 1 Active not recruiting
NCT04042701 2025-11-18
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
Daiichi Sankyo
Phase 1 Active not recruiting
NCT07086768 2025-09-04
Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metastatic Solid Tumors
The University of Texas Health Science Center at San Antonio
Phase 1 Not yet recruiting
NCT05765851 2025-05-11
A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors
Daiichi Sankyo
Phase 1 Active not recruiting
NCT03523572 2025-01-27
Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer
Daiichi Sankyo
Phase 1 Completed
NCT06331169 2024-08-30
Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer
Fudan University
Phase 1 Recruiting
NCT02564900 2024-01-22
Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors
Daiichi Sankyo
Phase 1 Completed
NCT03383692 2023-12-11
Study of DS-8201a for Participants With Advanced Solid Malignant Tumors
Daiichi Sankyo
Phase 1 Completed
NCT03368196 2022-11-03
DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein
Daiichi Sankyo
Phase 1 Completed
NCT03366428 2022-04-12
Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer
Daiichi Sankyo
Phase 1 Completed